Browsing Category
Pharma Industry News
4723 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears
Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Avalyn Pharma advances AP02 into Phase 2 trials, testing inhaled drug delivery as a safer IPF strategy. Discover what this means for the fibrosis market.
Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Discover what this means for trial execution and survival outcomes.
Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows
Atossa Therapeutics widened its 2025 loss as Z-endoxifen spending rose and rare disease optionality expanded. Read what this could mean for ATOS.
Akeso moves bispecific ADCs into Phase II as IO 2.0 combination strategy enters mid-stage development
Akeso (9926.HK) advances bispecific ADC combos with cadonilimab and ivonescimab into Phase II. Read what this means for oncology competition and the stock.
How China’s lymphoma treatment landscape could evolve with HMPL-760’s registrational study
Can HMPL-760 reshape lymphoma treatment? Explore HUTCHMED’s Phase III strategy and what it means for BTK competition.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
Clover Biopharmaceuticals stock in focus as new RSV re-vaccination data targets a gap GSK has not solved
Clover Biopharmaceuticals says new RSV re-vaccination data beat Arexvy in older adults. Read what this could mean for the adult vaccine market.
How the OptimUM-02 trial timeline may influence investor and clinical sentiment in ocular oncology
IDEAYA Biosciences nears darovasertib data. Find out how this Phase 3 readout could reshape metastatic uveal melanoma treatment today.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.